Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Monday 10 September, 2001

Xenova Group PLC

Research Update

Xenova Group PLC
10 September 2001


Xenova Group plc

Anti-Nicotine Addiction Vaccine TA-NIC Enters Phase I Trials

Slough, UK, 10th September 2001 - Xenova Group plc (Nasdaq NM: XNVA; London
Stock Exchange: XEN) today announces that its novel therapeutic vaccine,
TA-NIC, which is being developed for the treatment of nicotine addiction, has
entered Phase I clinical trials.

The Phase I study is a double-blind, randomised, placebo-controlled study to
assess the safety, tolerability and immunogenicity of the TA-NIC vaccine in
both smokers and non-smokers.  The vaccine is administered by intra-muscular
injection.  In the first instance, two different dose levels are to be
investigated in a variety of dosing regimens.

TA-NIC is believed to be the first anti-nicotine addiction vaccine to enter
clinical testing.  TA-NIC uses a novel mode of action whereby it seeks to
prevent nicotine from entering the brain.  Currently available therapies for
nicotine addiction include nicotine replacement therapy, delivered via skin
patches, chewing gum or inhalers or treatment with the nicotine-free drug

Over 1 billion people worldwide smoke tobacco products (World Health
Organisation), resulting in approximately 3 million deaths annually (American
Cancer Society, 1996) from smoking-related disease.  Despite the known health
risks, many people who want to give up smoking cigarettes (or other tobacco
products) find it very difficult to do so, due to the addictive properties of
nicotine and the unpleasant withdrawal symptoms.  Approximately 17 million
smokers in the US alone attempt to quit each year (Center for Disease Control
and Prevention).

TA-NIC is Xenova's second anti-addiction drug candidate to enter clinical
trials.  An anti-cocaine addiction vaccine, TA-CD, is currently in Phase II
clinical development in the US.   Other Xenova products currently undergoing
clinical trials target the treatment of cancer and infectious diseases.

David Oxlade, Xenova's Chief Executive, said: 'Most people who want to stop
smoking find it very hard to do so, even though they may be aware of the risks
involved.  Although at an early stage of development, if TA-NIC can be of
assistance it could have an important contribution to make in reducing the
burdens that smoking imposes.'


Xenova Group plc                                 Financial Dynamics
Tel: +44 (0)1223 423 413                         Tel: +44 (0)20 7831 3113
John St Clair Roberts: Medical Director          David Yates/Fiona Noblet
Nick Hart: Commercial Director

Also:                                                BMC Communications

(on 10th September only)                             Tel: 001 212 477 9007
Tel: 001 212 477 9007
David Oxlade: Chief Executive Officer
Daniel Abrams: Finance Director
Hilary Reid Evans: Corporate Communications

Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic
area of cancer, with a secondary focus on infectious, autoimmune and
cardiovascular diseases.  The Group has a well-established track record in the
identification, development and partnering of innovative products and
technologies and has partnerships with a number of major pharmaceutical
companies including Glaxo SmithKline, Lilly, Pfizer, QLT Inc and Celltech.

For further information about Xenova and its products please visit the Xenova
website at


a d v e r t i s e m e n t